Prostate Cancer

Serious Side Effects Noted in Commonly Prescribed Prostate Cancer Drug

Treatment of benign prostatic hyperplasia (BPH) with the commonly prescribed Avodart (Dutsteride) may put men at an increased risk for diabetes, elevated cholesterol levels, non-alcoholic fatty liver disease (NAFLD) and worsening erectile dysfunction. Physicians should be fully aware of these new findings according to the researchers, and to discuss with their patients the potential adverse side effects of Avodart on metabolic and sexual function before prescribing it. The study appears in the journal Hormones Molecular Biology and Clinical Investigations. As men age, their prostate enlarges. This condition often results in urinary retention or other lower urinary tract symptoms, such as reduced urinary flow which results in waking up several times at night to urinate. To help improve symptoms, men are often prescribed an alpha blocker, such [...]

2017-12-13T13:37:20+00:00 July 4th, 2017|

Key ingredients to thwart the growth of prostate cancer found in certain foods

When you dine on curry and baked apples, enjoy the fact that you are eating something that could play a role starving -- or even preventing -- cancer. New research from The University of Texas at Austin identifies several natural compounds found in food, including turmeric, apple peels and red grapes, as key ingredients that could thwart the growth of prostate cancer, the most common cancer afflicting U.S. men. Published online this week in Precision Oncology, the new paper uses a novel analytical approach to screen numerous plant-based chemicals instead of testing a single agent as many studies do, discovering specific combinations that shrink prostate cancer tumors. "After screening a natural compound library, we developed an unbiased look at combinations of nutrients that have a [...]

2017-12-13T13:37:20+00:00 June 13th, 2017|

Hal & Mary: Another Happy HIFU Story

Posted on HIFU Prostate Services 5/27/2017 If you ask Hal Plimpton, he will tell you that he is a semi-retired, international logistics consultant who has owned and operated his own business for many years. If his wife, Mary, happens to hear him say he is “semi” retired, she will laugh and probably roll her eyes. “He was supposed to retire 15 years ago, but he’s still working,” said Mary. However, one thing that Hal and Mary can agree on is that they made a good treatment decision several years ago when Hal was diagnosed with prostate cancer. “I could tell that he felt really good about HIFU (high intensity focused ultrasound). He had confidence in the technology that it was going to work. I was a [...]

2017-12-13T13:37:20+00:00 May 31st, 2017|

Doctor’s Own Prostate Cancer Diagnosis Leads to Early Intervention and Positive Results with HIFU

Dr. Michael Lazar of California HIFU shares the story of how friend and fellow surgeon Dr. Robert Pugach underwent HIFU treatment for prostate cancer following an early diagnosis with the disease. Dr. Robert Pugach It’s the news no man wants to hear from a doctor, “… you have prostate cancer.” And when you are a practicing physician who receives this news, all the more room for concern. Dr. Robert Pugach, medical director of Pacific Coast Urology Medical Center was diagnosed with prostate cancer last year and opted to undergo HIFU treatment with urologist and prostate cancer specialist Dr. Michael Lazar of California HIFU earlier this month. What transpired is truly an inspirational account of one man’s journey from diagnosis to cure. Dr. Pugach [...]

2017-12-13T13:37:20+00:00 May 23rd, 2017|

New blood test better at predicting prostate cancer risk than PSA

A new blood test known as IsoPSA detects prostate cancer more precisely than current tests in two crucial measures -- distinguishing cancer from benign conditions, and identifying patients with high-risk disease. By identifying molecular changes in the PSA protein, the findings of this study suggest that once validated, use of IsoPSA may reduce the need for biopsy, and may lower the likelihood of overdetection and overtreatment of nonlethal prostate cancer. A team of researchers from Cleveland Clinic, Louis Stokes Cleveland VA Medical Center, Kaiser Permanente Northwest, and other clinical sites have demonstrated that a new blood test known as IsoPSA detects prostate cancer more precisely than current tests in two crucial measures -- distinguishing cancer from benign conditions, and identifying patients with high-risk disease. By [...]

2017-12-13T13:37:20+00:00 May 16th, 2017|

Focused ultrasound therapy is here: Are you ready?

A new, highly disruptive therapeutic technology called focused ultrasound is transforming – standards of care around the globe. Published by Neal Kassell on LinkedIn Distinguished Professor of Neurosurgery at University of Virginia In this series, we asked speakers at the Milken Institute Global Conference to answer: How does one build a meaningful life in the age of technological disruption? Join the conversation by writing your own article here and including #MIGlobal. A new, highly disruptive therapeutic technology called focused ultrasound is slowly but definitively influencing – and on the verge of transforming – standards of care around the globe. This game-changing, noninvasive treatment option for a wide variety of serious medical disorders has the potential to be an alternative or adjunct to surgery, radiation therapy, drug delivery, [...]

2017-12-13T13:37:20+00:00 May 4th, 2017|

Common Prostate Cancer Therapy May Trigger Dementia

A new analysis of patients who have undergone treatment for prostate cancer shows a connection between androgen deprivation therapy (ADT) -- a testosterone-lowering therapy and a common treatment for the disease -- and dementia, according to researchers from the Perelman School of Medicine at the University of Pennsylvania. Their previous studies have shown men who undergo ADT may be at an increased risk of dementia, including Alzheimer's disease, compared to men who were not treated with the therapy. This new analysis -- the largest of its kind ever performed on this topic -- shows that all existing studies taken together support the link to dementia and show a possible link to Alzheimer's. The findings are published this week in Prostate Cancer and Prostatic Diseases. "Since [...]

2017-12-13T13:37:20+00:00 April 4th, 2017|

Study reveals genetic connection to aggressive prostate cancer

An international study published in the Journal of the National Cancer Institute has identified a genetic connection to the aggressive form of prostate cancer. The study showed a threefold increase in the risk of aggressive prostate cancer for men with the genetic mutation. The frequency of the gene variants varied from 6 to 14% of the population of men with prostate cancer. Much like the association between BRCA gene mutation and the risk for breast cancer in women changed the approach to treatment/ prevention, the identification of the Kallikrein 6 gene region may change the course of prostate cancer care through a blood test developed by the Lunenfeld-Tanenbaum Research Institute. The study was led by Dr. Alexandre Zlotta, Director of Uro-Oncology at Mount Sinai Hospital, [...]

2017-12-13T13:37:20+00:00 March 21st, 2017|

Researchers target cholesterol to stop prostate cancer

Advanced prostate cancer and high blood cholesterol have long been known to be connected, but it has been a chicken-or-egg problem. Now a team led by researchers at the Duke Cancer Institute have identified a cellular process that cancer cells hijack to hoard cholesterol and fuel their growth. Identifying this process could inform the development of better ways to control cholesterol accumulation in tumors, potentially leading to improved survival for prostate cancer patients. The findings are published online this month in the journal Cancer Research. "Prostate cancer cells, as well as some other solid tumors, have been shown to contain higher cholesterol levels than normal cells," said senior author Donald McDonnell, Ph.D., chairman of the Department of Pharmacology and Cancer Biology at Duke. "All cells [...]

2017-03-01T10:01:29+00:00 March 1st, 2017|

New discovery may lead to blood test predicting and preventing prostate cancer spread

University of Adelaide researchers have uncovered a new pathway which regulates the spread of prostate cancer around the body. Published in the journal Cancer Research, the discovery has potential to lead to the development of a blood test that could predict whether cancer will spread from the prostate tumour to other parts of the body. The research also reveals potential new targets for drugs that may inhibit the spread of cancer. "Prostate cancers only kill men after they have spread or 'metastasised' from the prostate," says project leader Dr Luke Selth, Senior Research Fellow at the University of Adelaide's Dame Roma Mitchell Cancer Research Laboratories and a member of the Freemasons Foundation Centre for Men's Health. "The identification of markers that accurately predict, at an [...]

2017-02-21T08:57:11+00:00 February 21st, 2017|